- Home
- PRQR vs ANTX Comparison
PRQR vs ANTX Comparison
Compare PRQR & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRQR | ANTX |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.5M | 170.6M |
| IPO Year | 2014 | 2022 |
Fundamental Metrics
Financial Performance| Metric | PRQR | ANTX |
|---|---|---|
| Price | $1.50 | $3.82 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $7.25 | $2.00 |
| AVG Volume (30 Days) | ★ 566.6K | 215.7K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $13.92 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.33 | $1.00 |
| 52 Week High | $3.10 | $6.91 |
Technical Indicators
Market Signals| Indicator | PRQR | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.07 | 38.80 |
| Support Level | $1.37 | $1.06 |
| Resistance Level | $1.58 | $5.13 |
| Average True Range (ATR) | 0.11 | 0.39 |
| MACD | 0.00 | -0.11 |
| Stochastic Oscillator | 53.45 | 8.08 |
Price Performance
Historical ComparisonAbout PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.